Well, there isn't any all-in-one platform anywhere globally, like AT1, for any type of POCTs (none, I have checked many times and I keep an eye monthly across medical news, innovation webinars, market reports etc)...so this is the unique POCT tech that folks should be chasing down to partner and build multiple test channels for.
Absolutely I agree, there is plenty of competition for the 'test' aspect of any POCT - the strip/the purpose of X test that the platform may house. Exception being FebriDx as there is no other RDT like that for viral/bacterial check.
So unless the next test partner/s are dominant in a test sector, its going to be 1-2-3-4-5yrs path to commercialisation + expansion using AT1 platform
I agree with you about the OEM track...this is the bit that continues to worry me. AT1's IPO goals were to expand and grow its platform potential alongside HIV expansion.
HIV track, its doing great + AT1 is a bigger production company and has spare cash to spend on biz growth, staff, R&D. Mgmt has accomplished enormous amount of work in 18months and has lots planned ahead.
...but despite Covid19 infectious disease + general POCTs demand that continue to grow, AT1's platform potential partners don't seem to go beyond the 'initial' agreement/order qty and keep dropping back to cheaper, mass produced suppliers, using traditional components. This worries me a bit.
Is OEM per device cost too expensive? Or is it maybe the wrong moment in time for this tech - despite POCTs being ever more in demand that people just wanna keep using what they are familiar with?
It seems like it will take another 2-4yrs for OEM biz to get some regular earners (exception being FebriDx which almost at take-off point).
